PharmaAI learned第一时间 that on November 15, Matwings Technology, an internationally leading AI protein design company, announced the completion of an A-round financing exceeding 100 million yuan.This round of financing was led byQiming Venture PartnersLeading investment,Yonghua Investment, Jingtao CapitalAnd existing shareholdersHerbal Capitaland other institutions followed suit. The funds raised will be mainly used for the development of self-research projects and general artificial intelligence for protein design.AccelProtein™ (From the Pro series artificial intelligence developed by the team of Hong Liang from Shanghai Jiaotong University) continuous iterative upgrades to ensure that Matwings Technology maintains a leading position in global technological innovation and market competitiveness.
Smart Pharmacy Bureau learned that Matwings Technology has been established for just over three years.Successful DeliveryMore than 30 protein design projects, including several Fortune 500 companies and many listed companies in China. The team has also expanded from a research and development focus to extensive integration with downstream applications, quickly establishing the company's technical barriers and industry influence.
AccelProtein™: Predict Protein Function, Revolutionize Protein Design
Proteins are omnipresent in our daily life and production, serving as the foundation for maintaining life activities and driving technological innovation. Protein products with excellent functions are the source of progress in many industries such as biomedicine, green energy, food health, and green chemical engineering.However, traditional methods often face challenges such as high cost, complex processes, and low success rates when obtaining high-performance proteins.
The innovation of Matwings Technology lies in its self-developed general artificial intelligence for protein design, AccelProtein™, which is able toDirectly predicting protein function breaks through the limitations of structure prediction methods represented by AlphaFold, which "can only predict structure but cannot design function," providing a completely new technical means for obtaining proteins with excellent functions, and standing out uniquely in the industry.。Public information shows that, compared with traditional protein engineering methods such as rational design and directed evolution, Matwings Technology's AccelProtein™ large model no longer relies on expert experience, with the positive rate increasing from 1% to 30%, and the total number of experimental samples decreasing from thousands to 100 or even fewer.The project delivery cycle has been compressed from 2-5 years to 2-6 months, truly solving the pain points of protein engineering in industrial applications.。
Focusing on Biopharmaceuticals and Synthetic Biology to Empower the Upgrading of Biomanufacturing Industry
Currently, Matwings Technology's general artificial intelligence for protein design, AccelProtein™, has achieved directed mining and evolution of proteins in numerous scenarios within biomedicine and synthetic biology, includingIndicators such as thermal stability, activity, affinity, tolerance to extreme pH, immunogenicity, and yield of proteinsSignificant improvement.
In the CMC stage of biopharmaceuticals, AccelProtein™ can enhance the activity, specificity, thermal stability, and pH stability of key tool enzymes and tool proteins; in the early large molecule screening stage, it improves the affinity and functional activity of fusion proteins, antibodies, and cytokines for their targets; in the candidate molecule optimization stage, it provides druggability index modification and property optimization (including improving molecular stability and reducing viscosity), precisely addressing critical pain points pharmaceutical companies face during R&D and production.In the field of synthetic biology, Matwings Technology relies on AccelProtein™ for enzyme modification, enzyme mining, and enzymatic process development, addressing the precise synthesis challenges of high-value molecules that are difficult to solve through chemical synthesis or natural extraction. It provides efficient and green AI-driven enzymatic solutions for fields such as pharmaceutical intermediates, fragrances, health product ingredients, and cosmetic raw materials.After more than three years of accumulation, Matwings Technology has successfully delivered over thirty protein design projects, serving leading companies in various industries such as innovative drugs, in vitro diagnostics, pharmaceutical intermediates, nutritional health, food and beverages, cleaning and textiles, and bio-agriculture.Taking the key raw material EPS-G7 for blood amylase detection as an example, Matwings Technology took only 4 months to increase the total transglycosylation activity of the key enzyme in the EPS-G7 synthesis process by 7 times, improve product specificity from 60% to 98%, and reduce hydrolytic activity by 33%.Production costs reduced to one-tenth of the price of imported products, helping customers break through the import monopoly and enhancing China's independent control and international competitiveness in pancreatitis diagnosis.Taking the affinity chromatography filler protein as an example, Matwings Technology also spent 4 months to increase the alkali resistance of the filler protein by 3 times, the binding capacity by 1 time, and the thermal stability by 8°C, not only...Helping customers save tens of millions of dollars in costs annually, and it marks the possibility of using affinity chromatography for purification at a low cost, which is of great significance for improving drug production efficiency and reducing production costs.In the future, Matwings Technology will deepen the application of its AI protein design technology, further accelerate innovation in the biopharmaceutical and synthetic biology fields, and promote biomanufacturing towards a more efficient and environmentally friendly direction.Recommended Reading
